# A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther)

> **NCT01512186** · — · UNKNOWN · sponsor: **Queen Mary University of London** · enrollment: 95 (estimated)

## Conditions studied

- Metastatic Clear Cell Renal Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01512186
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-07
- **Primary completion:** 2014-02
- **Final completion:** 2014-12
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2014-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01512186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01512186, "A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01512186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*